Results for “FDA”

The Hill Nathaniel Weixel Geopolitics

Senate committee sets key vote for Trump FDA nominee

The Senate Health Committee scheduled a key vote next week for Dr. Heidi Overton to serve as commissioner of the Food and Drug Administration (FDA), even as her path forward is not assured. According to a committee press release, the vote on Overton’s nomination is scheduled for Nov. 18. The committee will also vote on...

Read at The Hill

Quantum Computing Report Mohamed Abdel-Kareem

INmune Bio Engages Quantum Computing Inc. to Expand Drug Indication Discovery for XPro

INmune Bio and Quantum Computing Inc. are collaborating to use quantum optimization and AI for drug discovery. QCi's Dirac-3S quantum machine will analyze clinical data to find new disease indications for INmune Bio's neuroinflammation drug, XPro. This partnership aims to identify rare and pediatric disease indications for accelerated FDA review.

Read at Quantum Computing Report

BioPharma Dive BioPharma Dive staff

AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning

The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.

Read at BioPharma Dive

Tech in Asia Adinda Pryanka Startups

FDA-cleared device kills airborne microbes in hospitals

With US$3 million in new funding on the horizon, Biomoneta wants to bring its hospital-grade infection prevention technology to global markets.

Read at Tech in Asia

BioPharma Dive Jonathan Gardner

Beam’s base editing therapy for sickle cell hits goal in pivotal trial

The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.

Read at BioPharma Dive

Ars Technica Beth Mole

FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss

The risk appears small and data is mixed, but FDA wants patients to be aware.

Read at Ars Technica

STAT Biotech Elaine Chen

STAT+: GLP-1s are given an FDA warning for rare eye condition risk

The FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes referred to as an “eye stroke.”

Read at STAT Biotech

CBS News

FDA warns of rare vision-loss side effect from GLP-1 drugs

The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands.

Read at CBS News

CBS News

GLP-1s must now include warning for potential increased risk of vision loss, FDA announces

The FDA announced that GLP-1 weight loss drugs will now include warning labels indicating a potential increased risk of vision loss.

Read at CBS News

BioPharma Dive Jacob Bell

Bayer wins FDA nod for a new kind of blood thinner

Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention.

Read at BioPharma Dive

STAT Biotech Elaine Chen and Elizabeth Cooney

STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke

Bayer's drug is the first in a novel class of medications designed to prevent blood clots without increasing risk of bleeding.

Read at STAT Biotech

arXiv (research papers) Yihan Hank Tang University of Pennsylvania SI

TrialDesignBench: Benchmarking Language Models for Phase-I Trial Design Against Clinical Knowledge

AI is used in much of the clinical trial pipeline. However, selecting the statistical design of a trial, a crucial step that determines how drug doses are tested on humans and evaluated, has seen almost no AI progress. LLMs appear to be a natural fit given their strengths in biomedical knowledge and statistical reasoning. Nevertheless, there is currently no appropriate way to evaluate such abilities because recent regulatory and methodological shifts, most notably FDA's…

Read at arXiv (research papers)

STAT Biotech Elaine Chen

STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition

The FDA on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition that's sometimes referred to as an "eye stroke."

Read at STAT Biotech

Journal articles (OpenAlex) Thomas E. Ichim, Neil H Riordan · Journal of Translational Medicine

Immunological aspects of mesenchymal stem cell therapy for ALS

Neuroinflammation contributes to ALS progression, yet effective immune-modulating therapies remain limited. Despite the enthusiasm regarding stem cell therapy as a means of regeneration, it is interesting that the first FDA approval for mesenchymal stem cells (MSC) was for immune modulation, graft versus host disease (GVHD), not rejuvenation. We focus here on the immunological mechanisms through which MSC, particularly via induction of regulatory T cells, may slow…

Read at Journal articles (OpenAlex)

Axios Andrew Pantazi Geopolitics

Blanche dismisses Means allegations as GOP's MAHA feud deepens

Attorney General Todd Blanche on Sunday dismissed former Trump health adviser Calley Means' corruption allegations against senior White House officials, even as a former FDA commissioner described pressure from tobacco lobbyists and a Republican congressman called for scrutiny. Why it matters: The feud inside President Trump's coalition raises a central question about Trump's health agenda: Were his advisers undermining it, as Means alleges, or were they carrying out the…

Read at Axios

Journal articles (OpenAlex) Sojin Bing, Takele Argaw, Megha Kaushal et al. · Nature Reviews Drug Discovery

Regulatory lessons from FDA review of approved AAV gene therapies

Read at Journal articles (OpenAlex)

STAT Biotech Margaret Manto

STAT+: Pharma critic Bernie Sanders is set to hold major sway over FDA funding bill

Sanders could use his role in crafting the FDA funding bill to push for reforms.

Read at STAT Biotech

AgFunderNews Elaine Watson

Fooditive in advanced talks to commercialize low-cal rare sugar 5-KDF

Fooditive has tested production at 75,000-L scale as it pursues licensing partners and awaits an FDA decision on its low-calorie sweetener.

Read at AgFunderNews

Green Queen (alternative protein) Anay Mridul

Formo, Those Vegan Cowboys Secure FDA GRAS Letter to Sell Cow-Free Casein in US

5 Mins ReadEuropean precision fermentation startups Formo and Those Vegan Cowboys have obtained a joint ‘no questions’ letter from the US FDA for their animal-free casein proteins. Four months after filing a joint notice confirming the Generally Recognized as Safe (GRAS) status of their respective precision-fermented casein proteins, Formo and Those Vegan Cowboys have now secured a

Read at Green Queen (alternative protein)